Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 10:9:940472.
doi: 10.3389/fvets.2022.940472. eCollection 2022.

Pharmacokinetics and bioequivalence of two cyclosporine oral solution formulations in cats

Yuxin Yang  1 , Jingyuan Kong  1 , Yu Liu  1 , Qinyao Wu  1 , Yuying Cao  1 , Jicheng Qiu  1 , Lu Zhang  1 , Xiaohui Gong  1 , Fuhua Zhao  2 , Xingyuan Cao  1   3 , Jianzhong Wang  4
Affiliations

Pharmacokinetics and bioequivalence of two cyclosporine oral solution formulations in cats

Yuxin Yang et al. Front Vet Sci. .

Abstract

The pharmacokinetic profiles and bioequivalence of two cyclosporine oral solutions were investigated in cats. Twenty-four cats were randomly allocated to two equally sized treatment groups in a randomized four-cycle, and dual-sequence cross-over design. Test and reference articles were orally administered in a single dose of 7 mg/kg Bodyweight. Serial blood samples were collected, and blood cyclosporine concentration was determined by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS/MS). No significant differences were present in the major pharmacokinetic parameters (Cmax, AUC0-last,) between the two formulations. The blood profiles of cyclosporine following the administration of both formulations were similar. The findings of the study suggested that the two articles were bioequivalent for cyclosporine oral solution.

Keywords: bioequivalence; cat; cyclosporine oral solution; four-cycle; pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Semilogarithmic plot of the cyclosporine plasma concentrations–time curves.
See this image and copyright information in PMC

References

    1. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. (2013) 172:351–6. 10.1007/s00431-012-1893-3 - DOI - PubMed
    1. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. . Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immun. (2014) 133:1626–34. 10.1016/j.jaci.2014.03.003 - DOI - PMC - PubMed
    1. Beltrani VS. The clinical spectrum of atopic dermatitis. J Allergy Clin Immun. (1999) 104:S87–98. 10.1016/S0091-6749(99)70050-3 - DOI - PubMed
    1. Olivry T, Steffan J, Fisch RD, Prelaud P, Guaguere E, Fontaine J, et al. . Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc. (2002) 221:370–7. 10.2460/javma.2002.221.370 - DOI - PubMed
    1. Griffin C, DeBoer D. The ACVD task force on canine atopic dermatitis (XIV): clinical manifestations of canine atopic dermatitis. Vet Immunol Immunopathol. (2001) 81:255–69. 10.1016/S0165-2427(01)00346-4 - DOI - PubMed